The PREVENT program is a peer-reviewed agent development program designed to support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. All interested researchers with novel concepts are eligible to apply. PREVENT is not a grant program, but allocates NCI contract resources and expertise to generate data and materials, which are used by the applicants for further development. PREVENT’s current research priority areas include immunoprevention, chemoprevention, and clinically translatable biomarkers.
Read more About PREVENT.
Application Instructions
The PREVENT application submission deadlines are twice per year in November and May.
At the present time, we are unable to provide the next submission deadline. We apologize for any inconvenience.
Please apply using the PREVENT Application System.
Supported Projects
134 Projects from PREVENT Cycles 1 through 26:
- 79 Chemoprevention projects
- 46 Immunoprevention projects
- 9 Biomarker projects
Read more about supported projects and supported prevention approaches.
Available Resources
- Efficacy
- Toxicology
- Regulatory Support
- Current Good Manufacturing Practice (CGMP)
- DCP Repository
Program Administration
- Governance Structure
- Technology Transfer Considerations
News and Events
Translational Advances in Cancer Prevention Agent Development (TACPAD) – 3rd Biennial Virtual Meeting
Date Posted: April 26, 2024
DCP Participation at American Association for Cancer Research (AACR) Annual Meeting, April 5-10, 2024
Date Posted: March 12, 2024
DCP/PREVENT-funded Project Presentations at the 2024 AACR Annual Meeting
Date Posted: March 12, 2024
Immune Interception Approaches for Individuals at Risk for Pancreatic Cancer
Date Posted: December 13, 2023
Chief, Chemopreventive Agent Development Research Group Position Available
Date Posted: August 21, 2023